Dermatomyositis post vaccine against SARS-COV2

Springer Science and Business Media LLC - Tập 6 Số 1 - 2022
Adolfo Camargo Coronel1, Francisco Javier Jiménez Balderas1, H. Quiñones-Moya1, Mario Raúl Hernández Zavala1, Pedro Mandinabeitia Rodríguez1, José Ramiro Hernández Vázquez1, Sandy Zamora Zarco1, Sergio De Jesús Aguilar Castillo1
1Rheumatology Department, “Centro Medico Nacional Siglo XXI”, Mexico City, Mexico

Tóm tắt

Abstract Background Dermatomyositis belongs to an infrequent group of diseases predominantly found in patients older than 40 years old and is characterized by dermal and muscular findings. This disease presents itself as proximal, ascending and symmetric weakness and typical dermatosis with findings such as elevated muscle enzymes, altered electromyography and typical changes in muscle biopsy; as of today, the etiology of the disease in unknown. The COVID-19 vaccine has been a fundamental tactic to achieve control of the coronavirus (SARS CoV2), and it’s clear that the benefits of getting the vaccine overweight the risks that might come along with it. Although rare, all adverse effects should be reported, this could help us to understand the elusive pathophysiology of inflammatory idiopathic myopathy. Case presentation In this text we will describe the case of a patient with dermatomyositis who was vaccinated against SARS CoV2 with BNT162b2 mRNA (Pfizer-BioNTech), showing a temporal relation between the vaccination and the beginning of her symptoms. We realized all the diagnostic approach to the suspected disease including electromyography, muscle biopsy and laboratory findings, corroborating the diagnosis. The patient received standard treatment for this disease (steroid therapy) and have a classic slow improvement. Conclusions Although it´s not possible to confirm a direct correlation between the vaccine and the onset of the disease, we considered that there are enough data to suspect that this could be a trigger event and therefore should always be considered a possible cause for a case of inflammatory idiopathic myopathy.

Từ khóa


Tài liệu tham khảo

Lundberg I, de Visser M, Werth V. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269–78.

Riddell V, Bagby S, McHugh N. Myositis autoantibodies: recent perspectives. Curr Opin Rheumatol. 2020;32(6):548–52.

Stübgen J. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014;13(1):31–9.

United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 6/25/2021, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on Jul 8, 2021 10:57:31 PM

Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. Am J Transplant. 2021;21(3):1332–7.

Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep. 2021;14(6):e243629.

Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep. 2021;14(7):e243975.

Bano F, Badugama B, Chandra D. Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience. BMJ Case Rep. 2021;14(7):e243894.

Suresh P, Petchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021;14(6):e243931.

Uwaydah A, Hassan N, Abu Ghoush M, Shahin K. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Reports. 2021;14(4):e242060.

Patel S, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Reports. 2021;14(4):e242956.

Mayoclinic.org. 2022. U.S. COVID-19 vaccine tracker: See your state’s progress. https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker/. Accessed 27 January 2022

Fernando P, Stephen J, Nicholas K, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, and Cols. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955–1964

Gerberding JL, Haynes BF. Vaccine innovations. Past and future. N Engl J Med. 2021;384(5):393–6.

Florian K, Komal S, Hala A, et al. Antibody responses in seropositive persons after a single dose of SARS- CoV-2 mRNA vaccine. N Engl J Med. 2021;384:14.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 6 Số 1

Thông tin tác giả